No Data
No Data
Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Shares Lagging The Market But So Is The Business
With a price-to-earnings (or "P/E") ratio of 17.5x Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) may be sending bullish signals at the moment, given that almost half of all companies in China ha
Jianmin Group (600976.SH) announced first-quarter results, net profit of 99.52 million yuan, a year-on-year decrease of 0.04%
Jianmin Group (600976.SH) disclosed its report for the first quarter of 2024. The company achieved 9.7 revenue during the reporting period...
Jianmin Group (600976.SH) will distribute 1.2 yuan per share in 2023. The stock registration date is April 25
Jianmin Group (600976.SH) issued an announcement that the company will implement the 2023 annual equity distribution, distributed per share...
Jianmin Group (600976.SH): The phase II clinical trial of the company's product Tongzheng Granule is in the summary stage
Gelonghui April 16 丨 Some investors asked Jianmin Group (600976.SH) through an interactive platform: How is your company's clinical progress in Tongzheng Granule? How long until launch? Jianmin Group (600976.SH) replied: The second phase clinical trial of the company's product Tongzheng Granule is in the summary stage. There is some uncertainty in the development of new drugs. Investors are kindly requested to pay attention to investment risks.
Jianmin Pharma Gets Nod to Market Asthma Drug
Jianmin Pharmaceutical Group (SHA:600976) obtained approval from China's National Medical Products Administration to market its terbutaline sulfate atomized inhalation product, the company said in a T
Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Solid Profits Have Weak Fundamentals
Investors were disappointed with Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) earnings, despite the strong profit numbers. We think that the market might be paying attention to some underlyi
No Data